Skip to main content

Table 2 Main Patient Characteristics Associated With 3- and 6-Month Mortality From Intensive Care Unit Admission in Patients Who Were Discharged Alive From ICU (Univariate Analysis)

From: Factors associated with survival of patients with solid Cancer alive after intensive care unit discharge between 2005 and 2013

Variable

At 3 Months n = 249* (83 deaths)

At 6 Months n = 248* (102 deaths)

OR (95%CI)

p-value

OR (95%CI)

p-value

Patient Characteristics

 Gender Female (ref = male)

1.12 (0.63–1.99)

0.69

0.91 (0.52–1.59)

0.75

 Age (per year)

1.02 (1–1.04)

0.13

1.01 (0.99–1.04)

0.17

ECOG-PS (miss. = 10)

 

< 0.01

 

< 0.01

 - 0–1

1.00

 

1.00

 

 - 2

1.83 (0.96–3.5)

 

2.12 (1.15–3.9)

 

 - 3–4

4.86 (2.38–9.95)

 

5.07 (2.48–10.39)

 

Charlson comorbidity index (per point)

1.02 (1–1.03)

0.80

0.94 (0.82–1.09)

0.44

Cancer Characteristics

Type of cancer

 - Digestive (ref = absence)

1.22 (0.69–2.14)

0.50

1.05 (0.61–1.82)

0.86

 - Thoracic (ref = absence)

1.49 (0.83–2.67)

0.19

1.9 (1.07–3.36)

0.03

 - Head and Neck (ref = absence)

0.42 (0.17–1.06)

0.07

0.38 (0.16–0.92)

0.03

 - Gynecological (ref = absence)

1.13 (0.49–2.56)

0.78

1.1 (0.5–2.45)

0.81

 -Genito-urinary (ref = absence)

1.0 (0.43–2.33)

1

0.7 (0.3–1.63)

0.41

 - Other (ref = absence)

0.68 (0.26–1.80)

0.44

0.93 (0.39–2.24)

0.87

Metastatic disease (miss. = 12) (ref = absence)

2.29 (1.33–4)

< 0.01

2.46 (1.45–4.16)

< 0.01

Previous anticancer treatment

 - Surgery (ref = absence)

0.60 (0.35–1.02)

0.06

0.60 (0.36–1)

0.05

 - Radiotherapy (ref = absence)

0.71 (0.4–1.27)

0.25

0.86 (0.5–1.48)

0.58

 - Chemotherapy (ref = absence)

0.71 (0.42–1.21)

0.20

1 (0.6–1.67)

0.99

Cancer status (miss. = 6)

 

0.19

 

0.03

 - Controlled or in remission for < 5 years

1.00

 

1.00

 

 - Newly diagnosed / recurrence

1.41 (0.73–2.69)

 

1.65 (0.88–3.08)

 

 - In progression

1.92 (0.95–3.89)

 

2.57 (1.29–5.11)

 

ICU Characteristics

 Reason of ICU admission

  Tumor progression (ref = absence)

2.67 (1.47–4.88)

< 0.01

2.72 (1.49–4-95)

< 0.01

  - Thrombotic event (ref = absence)

1.66 (0.63–4.39)

0.30

2.44 (0.91–6.54)

0.08

  - Bleeding (ref = absence)

1.13 (0.49–2.56)

0.78

1.1 (0.5–2.45)

0.81

  - Complications of anticancer treatment (ref = absence)

0.84 (0.45–1.59)

0.60

1.14 (0.63–2.06)

0.67

  - Not related to cancer (ref = absence)

0.53 (0.31–0.91)

0.02

0.4 (0.24–0.68)

<.01

 SAPS II (per point)

1.02 (1–1.03)

0.03

1.02 (1.0–1.03)

0.02

Supportive Care

 - Vasopressors (ref = absence)

1.17 (0.68–2.03)

0.57

1.04 (0.61–1.77)

0.88

 - Invasive ventilation (ref = absence)

0.8 (0.46–1.37)

0.41

0.78 (0.47–1.31)

0.35

 - Renal replacement therapy (ref = absence)

0.93 (0.36–2.37)

0.87

0.82 (0.33–2.03)

0.66

TLD before ICU discharge (ref = absence)

6.53 (3.11–13.74)

< 0.01

3.22 (1.25–8.29)

< 0.02

Length of stay in ICU (per day)

0.99 (0.96–1.02)

0.42

0.99 (0.96–1.01)

0.30

  1. *Five patients were lost to follow-up at 1, 30, 62, 64 and 129 days, respectively. They were excluded for the analyses
  2. CI confidence interval, ICU intensive care unit, OR odds ratio, miss. missing data, PS performance status, TLD treatment limitation decision